Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Napp Pharmaceuticals Limited
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteoarthritis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| LEAN (this asset) | Napp Pharmaceuticals Limited | Approved | BB · 68 |
| Naltrexone | Brigham and Women's Hospital | P4 | BBB |
| Buprenorphine | Mundipharma Pte Ltd. | P4 | BBB |
| Oxycodone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P4 | BBB |
| Fentanyl | Janssen Pharmaceutica | P4 | BBB |
| Duloxetine | The Catholic University of Korea | P4 | BBB |
| Liraglutide | Henrik Gudbergsen | P4 | BBB |
| Tapentadol | Janssen Scientific Affairs, LLC | P4 | BB |
| Dextrose Solution | Kastamonu University | P4 | BB |
+39 more in the Osteoarthritis cohort
Other indications for LEAN
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vertebral Column Disorder | — | P4 | BB · 68 |
| Sickle Cell Disease | — | P4 | B · 60 |
| Breast Disorder | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. LEAN in Osteoarthritis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lean-osteoarthritis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →